Latest Hotspot

Ionis announces encouraging results from the current ION582 trial for Angelman syndrome

20 November 2023
3 min read

Ionis Pharmaceuticals, Inc. revealed the successful completion of participant recruitment and encouraging early results from Part 1 of the continuous HALOS Phase 1/2a investigation of ION582 (BIIB121) in the context of Angelman syndrome.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. 图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

ION582 generally showed good tolerability in the study, demonstrating promising trends in electroencephalogram functioning and early indications of beneficial clinical advancements, which will require verification after a full dataset analysis scheduled for mid-2024. The insights were shared at the FAST Summit, with the presentation being accessible at the provided link.

Angelman syndrome is the result of a missing action in the gene UBE3A. ION582 aims to activate the dormant paternal UBE3A allele, thus enhancing the UBE3A protein production in the brain. Globally, Angelman syndrome is estimated to affect one person in every 12,000 to 20,000. The symptoms involve severe developmental setbacks in motor, language, and cognitive functionalities, as well as seizures and ataxia. It is a critical neurodevelopmental condition that manifests in early childhood, rendering the affected individual entirely reliant on a caregiver.

"The successful enrollment completion in the HALOS trial for Angelman syndrome and preliminary positive clinical findings are sources of hope," Ionis' Chief Scientific Officer and Executive Vice President Dr. Frank Bennett remarked.

"Next year, in the mid-part of the year, we expect to examine the study results. These results will guide us in determining the subsequent developmental phase of ION582. In light of the severe neurodevelopmental gaps and hurdles that people with Angelman syndrome and their caregivers confront, there is a dire need for new treatment breakthroughs in the community. We are excited to be part of this progress, in collaboration with the community, research scholars, regulators, and Biogen, our partners," he added.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, Word, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 19, 2023, there are 11 investigational drugs for the UBE3A target, including 1 indications, 14 R&D institutions involved, with related clinical trials reaching 5, and as many as 840 patents.

ION582 has received Orphan Drug Designation in the U.S. and is being developed by Ionis under a strategic collaboration with Biogen. The HALOS Phase 1/2a trial is evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in addition to certain clinical outcomes measures. ION582 is administered intrathecally into the cerebral spinal fluid with a lumbar puncture.

图形用户界面, 文本, 应用程序

描述已自动生成

First Participant Treated in Phase III Trial of Prostate Cancer Therapy TLX591 in ProstACT GLOBAL Study
Latest Hotspot
3 min read
First Participant Treated in Phase III Trial of Prostate Cancer Therapy TLX591 in ProstACT GLOBAL Study
20 November 2023
Initial Participant Receives Treatment in Phase III ProstACT GLOBAL Trial for Antibody-driven Prostate Cancer Candidate Therapy, TLX591.
Read →
GB-1211: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
GB-1211: A Quick Look at Its R&D Progress and Clinical Results from the 2023 AACR
20 November 2023
On 14 Apr 2023, the clinical trial evaluating exarafenib (KIN-2787) in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma was reported at the AACR Congress.
Read →
Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran
Latest Hotspot
3 min read
Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran
20 November 2023
Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran, a potential RNAi treatment, designed for addressing hypertension in individuals with significant cardiovascular risk.
Read →
Anthos Therapeutics' Abelacimab, a Factor XI/XIa inhibitor, demonstrated a 67% reduction in major or clinically relevant non-major bleeding compared to Rivaroxaban in atrial fibrillation patients
Latest Hotspot
3 min read
Anthos Therapeutics' Abelacimab, a Factor XI/XIa inhibitor, demonstrated a 67% reduction in major or clinically relevant non-major bleeding compared to Rivaroxaban in atrial fibrillation patients
20 November 2023
Abelacimab 150 mg, a unique Factor XI/XIa inhibitor from Anthos Therapeutics, showcased a 67% decline in significant or notably relevant non-major bleeding versus Rivaroxaban in atrial fibrillation patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.